MS Active Source

Treatment

• Introduction
• Introduction to MS
• MS treatments
  • Intro to MS treatments
  • Interferons
  • Avonex
  • Betaferon
  • Rebif
  • Glatiramer acetate
  • Copaxone
  • Natalizumab
  • Tysabri
  • Treatment of relapses
  • Risk-sharing scheme
  • Progressive MS
• Positive approach
• Newly diagnosed?
• Relative with MS
• Links
• Principles of treatment

Copaxone (Glatiramer Acetate) ( refT3 )

The active ingredient of Copaxone , glatiramer acetate, is a synthetic compound of four amino acids. Copaxone may be given to reduce relapses in people with relapsing-remitting MS. Such people should be ambulatory (able to walk) and have had at least two relapses in the last 2 years.

Copaxone is a suitable treatment for people with RRMS who have had at least two attacks of neurological dysfunction over the proceeding two-year period.

Copaxone is given as a daily subcutaneous injection (under the skin). The dose is 20 mg (milligrams). Decisions about the length of treatment should be made by the treating physician on an individual basis.

Licensed in 2002, Copaxone is manufactured by Teva Pharmaceuticals Ltd.

Use of this product will be determind by your neurologist according to guidance layed out in the risk-sharing scheme. More information can be found by going to   www.mstrust.org.uk

More detailed prescribing information on Copaxone can be found by going to www.medicines.org.uk. Typing Copaxone into the search box and pressing Go will bring you to the patient information leaflet usually packaged with the drug.

Quick Links

• Treatment rights
• Your questions
• Glossary
• Making the most of treatment
• Newly diagnosed

Supported by